Screenshot 2021-06-15 at 10.07.07

Biotech innovator Da Volterra leverages Solara to de-risk their clinical trial and optimize commercial strategy.

Challenged by a strict enrollment limit of 1,100 patients, Da Volterra had a sample size re-estimation (SSR) design that only produced marginal gains in power over the fixed sample size.

Facing the risk that a sub-optimal design would prevent a good drug from reaching patients, Da Volterra’s Chief Medical Officer sought a way to consider options that conventional wisdom would ignore.

Working with Cytel’s statistical consultants and their powerful new trial strategy platform Solara, in less than 2 hours Da Volterra was able to examine:

  • 151.2 million patient lives simulated
  • 1,512 combinations of design options and scenario variants

Find out how Da Volterra was able to use Solara’s revolutionary capabilities to rapidly prioritize design options and confidently select a low-risk trial design within hours.

Please enter your contact details to download the case study.

Group 668

151.2 million

patient lives simulated

Group 667

1,512 combinations

of design options and scenario variants

Group 669

2-hours

Ready for examination in less than